DYN Reports $62.4M Q1 Revenue, $134.6M Cash, Advances z-rostudirsen to BLA Filing in Q2 2026, Initiates Phase 3 HARMONIA Trial for z-basivarsen
Dyne Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $18.63
-4.9% in 7d after detection
Post-detection moves
1h
—
1d
-0.5%
3d
-1.0%
7d
-4.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS